About us

Home

About us

About Maxhealth Innovative Meditech

We are an innovative healthcare company providing a complete portfolio of non-invasive

diagnostic and therapeutic solutions for reflux disease.

Our Mission

To empower individuals and clinicians by simplifying reflux disease management through innovative,

non-invasive solutions that are accurate, accessible, and patient-centric.

Our Goal

To become the global partner of choice in reflux care, advancing diagnostics and treatment

to improve patient outcomes and quality of life worldwide.

Company Introduction

Maxhealth Innovative Meditech (Wuxi) Ltd is a patient-centered reflux care company dedicated to providing an end-to-end diagnostic and treatment solution for people suffering from GERD.

The company was founded in 2017, building on the decades of experience and resources of its parent company, Maxhealth Medical Group — established in Wuxi in 2009, listed on the NEEQ in 2016 (stock code: 836163), and owner of a 65,000 m² life science park, four R&D centers (two in China and two overseas), and a global team of over 200 professionals. With deep expertise in clinical research, academic promotion, channel development, and commercialization, the Group provided the foundation from which Maxhealth Innovative Meditech was built.

With decades of shared experience and a genuine commitment to patient well‑being, Maxhealth Innovative Meditech seeks to be a meaningful contributor to improving the lives of those affected by reflux disease around the world.

Our Team

Our team integrates expertise from both the UK and China, with leadership holding Ph.D. degrees in related fields. The foundation of our technology stems from the pioneering work of Prof. Peter Dettmar, a world‑renowned authority in reflux disease. Prof. Dettmar serves as Honorary Professor at the Department of Pharmaceutical Sciences, University of Nottingham, and previously held the position of Director of Research at the Center for Voice and Swallowing Disorders, Wake Forest University Baptist Medical Center, USA. He was also Global R&D Director at Reckitt in the UK, where he developed gastrointestinal products including the well‑known Gaviscon family.

Our specialists, with diverse backgrounds in clinical medicine, pharmacy, and bioengineering, collaborate across borders to drive innovation. Together, we are focused exclusively on advancing and delivering precision solutions in reflux management.

Our Qualification

The company is certified as a National High-Tech Enterprise and hold a portfolio of over 40 patents. Our flagship diagnostic products have obtained key market authorizations, including NMPA (China), CE (EU), and FDA (USA) clearances. The company's quality management system is certified to ISO 13485 standards, ensuring excellence from development to production.